Safety, efficacy and total cost of point-of-care manufactured anti-CD19 CAR-T cell therapy in India: VELCART trial by Hamenth Kumar Palani, Arun Kumar Arunachalam, Uday Kulkarni, Mohammed Yasar, Arvind Venkatraman, Swathy Palanikumar, Reeshma Nair Radhakrishnan, Majeela Solomon, Abirami Rajasekaran, Aniket Bankar, Phaneendra Venkateswara Rao Datari, Sushil Selvarajan, Anu Korula, Pradyot Dash, Dina Schneider, Louisa Wirthlin, Aby Abraham, Biju George, Vikram Mathews

Get full text